Greyson International, Inc. Hires Key Industry Professionals for Licensing Trilexon®

Greyson International, Inc. Hires Key Industry Professionals for Licensing Trilexon®

to Global Health, Beauty, Prescription and Non-Prescription Pharmaceutical Companies
BOCA RATON, Fla.—June 23, 2010 — Greyson International, Inc. (GYSN.PK) recently announced its June 16, 2010 conference call that it has hired three industry professionals as consultants who will assist in licensing Trilexon® to health and beauty companies around the world.

“We are very pleased to announce that three top consultants with an abundance of experience in the health and beauty industries in product development will be assisting us in licensing Trilexon®, our breakthrough delivery system for topical applications,” said Greyson International CEO Harvey Tauman. “Paul Thau, Cecile Meunier and Dr. Charlie Ware will each focus on a different area of licensing and product expansion for Greyson. We are highly confident in their abilities to reach the largest and most influential organizations in these industries and to offer their expertise in securing licensing opportunities for Trilexon®.”

Paul Thau will serve as a Research and Development Consultant for Greyson International. Thau was employed at Cosmair L’Oreal USA for over 22 years, where he served as Assistant Vice President of Cosmetic R&D and then as Senior Research Fellow. His cosmetic industry experience spans more than 50 years and includes R&D positions at Revlon, Bristol-Myers, CIBA Pharmaceutical and Warner-Lambert.

Thau has served the Society of Cosmetic Chemists in many capacities including Chairman of the New York chapter during 1971 and President of the national chapter in 1988. Later he was a member of the IFSCC Presidium and Scientific Committee. Paul is a Fellow of the Society of Cosmetic Chemists (SCC), and is a patentee or co-patentee on 14 issued U.S. patents. He was presented with the SCC Maison de Navarre Award in 2005. He currently has a cosmetic consulting company, PaCar Tech, which specializes in the areas of innovative product development, new cosmetic raw materials, technology transfer and technology acquisition.

Cecile Meunier will serve as a Marketing Consultant for Greyson International. Meunier is a seasoned cosmetics industry professional with proven abilities in business development as well as brand/product management. She possesses over 15 years of in-house corporate and consulting experience directing strategies for business expansion. Most recently, she was appointed by the Israel Economic Mission to provide regulatory guidance and further bridge the gap between Israeli cosmetics brands/manufacturers in their quest to expand their U.S. retail activity.

Meunier has directed the U.S. launch of Vichy (L’Oreal) and Boots to initiate their presence in the skincare departments within Brooks, CVS and Target. Some of her credits at L’Oreal included building a board of consulting dermatologists and advancing skin education with consumers via such organizations as the AAD, and providing new in-store skin diagnostic procedures.

In addition, Meunier has helped guide skincare companies, including AHAVA and Vizcaya (Brazil) in adapting their product lines, conducting market research and developing new product extensions. She also served as a key consultant to L’Occitane during the primary roll out of its freestanding boutique stores in the U.S.

Previously, Meunier worked in the corporate division of Ann Taylor, where she was responsible for portfolio management and marketing initiatives within the 500+ store chain for fragrance and cosmetics. In this role, she worked with top industry suppliers and perfumers at IFF and was responsible for all product development, earning her team the coveted FIFI award. From concept to execution, she directed strategic new launches, branding decisions and in-store promotions.

Meunier has also contributed to Global Cosmetics Industry Magazine and holds an MBA in Luxury Brand Management (Sponsored by LVMH and L’Oreal) from ESSEC International Business School in Paris, France.

Dr. Charlie Ware will serve as a Research and Development Consultant, Medical Division, for Greyson International. Ware is currently in private practice in Pembroke Pines and Boca Raton, Fla. Dr. Ware also has experience as an Allied Kinesiology Therapist and Manual Therapist, a Director of Oriental Medical Services and a Manual Therapist and Holistic Health Practitioner of Allied Kinesiology. He holds an M.S.T.O.M. and D.O.M. from the Atlantic Institute of Oriental Medicine; an H.H.P. from the Pacific College of Oriental Medicine; and H.H.P. in homeopathies from the International Professional School of Bodywork and Health and a B.S. and B.A. from the University of Maryland. He holds medical licensure with a Florida state license and a San Diego County H.H.P. license.

Ware is board certified by the National Certification Commission for Acupuncture and Oriental Medicine and the California Holistic Health Commission. He is a member of the American Acupuncture Council and the Florida State Acupuncture Association.
Greyson International has received confirmation that Trilexon® is safe for use based on thorough safety testing on an independent panel of participants. Trilexon® has received trademark approval and is patent pending. All Greyson products are manufactured in the U.S. The Company does not test its products on animals.

About Greyson International, Inc.
Greyson International, Inc. is a research, development and marketing company that markets health and beauty aid products. Greyson has developed a new delivery method, the Trilexon® system, which will improve the effectiveness of virtually every topical application in today’s cosmetic market and every over-the-counter topical drug application. Trilexon® is a registered trademark of Greyson International. For more information, visit, join the Greyson Facebook group page by visiting and searching “Greyson Products” or follow Greyson on Twitter at

This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.

Recommended Posts